ALLO
Income statement / Annual
Last year (2025), Allogene Therapeutics Inc's total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2025, Allogene Therapeutics Inc's net income was -$190.89 M.
See Allogene Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$22.00 K |
$95.00 K |
$156.00 K |
$114.09 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$12.36 M
|
$0.00
|
$0.00
|
$14.30 M
|
$0.00
|
$11.54 M
|
$5.03 M
|
$0.00
|
$0.00
|
| Gross Profit |
-$12.36 M
|
$22.00 K
|
$95.00 K
|
-$14.14 M
|
$114.09 M
|
-$11.54 M
|
-$5.03 M
|
-$1.50 M
|
$0.00
|
| Gross Profit Ratio |
0
|
1
|
1
|
-90.63
|
1
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$150.15 M
|
$192.30 M
|
$242.91 M
|
$256.39 M
|
$220.18 M
|
$192.99 M
|
$144.54 M
|
$151.86 M
|
$0.00
|
| General & Administrative Expenses |
$56.78 M
|
$65.21 M
|
$71.67 M
|
$79.31 M
|
$74.11 M
|
$65.26 M
|
$57.47 M
|
$40.98 M
|
$24.00 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$56.78 M
|
$65.21 M
|
$71.67 M
|
$79.31 M
|
$74.11 M
|
$65.26 M
|
$57.47 M
|
$40.98 M
|
$2.00 K
|
| Other Expenses |
-$12.36 M
|
$15.72 M
|
$13.25 M
|
-$14.30 M
|
$0.00
|
-$11.54 M
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$194.57 M
|
$273.22 M
|
$327.83 M
|
$321.40 M
|
$294.28 M
|
$246.70 M
|
$202.01 M
|
$192.84 M
|
$2.00 K
|
| Cost And Expenses |
$206.93 M
|
$273.22 M
|
$327.83 M
|
$335.69 M
|
$294.28 M
|
$258.24 M
|
$202.01 M
|
$192.84 M
|
$2.00 K
|
| Interest Income |
$19.29 M
|
$20.15 M
|
$18.31 M
|
$4.57 M
|
$1.71 M
|
$9.16 M
|
$17.35 M
|
$5.79 M
|
$0.00
|
| Interest Expense |
$1.08 M
|
$181.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3.36 M
|
$0.00
|
| Depreciation & Amortization |
$12.36 M
|
$13.64 M
|
$14.20 M
|
$14.30 M
|
$10.45 M
|
$11.54 M
|
$5.03 M
|
$1.50 M
|
$24.00 K
|
| EBITDA |
-$194.57 M |
-$243.33 M |
-$313.07 M |
-$321.24 M |
-$169.74 M |
-$238.68 M |
-$179.90 M |
-$206.76 M |
$22.00 K |
| EBITDA Ratio |
0
|
-11060.32
|
-3295.43
|
-2059.24
|
-1.49
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
-12418.14
|
-3449.86
|
-2150.87
|
-1.58
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$16.05 M
|
$16.05 M
|
$472.00 K
|
-$4.88 M
|
-$1.86 M
|
$8.02 M
|
$17.08 M
|
-$18.78 M
|
$0.00
|
| Income Before Tax |
-$190.89 M
|
-$257.15 M
|
-$327.27 M
|
-$340.41 M
|
-$182.05 M
|
-$250.22 M
|
-$184.93 M
|
-$211.62 M
|
-$24.00 K
|
| Income Before Tax Ratio |
0
|
-11688.5
|
-3444.89
|
-2182.14
|
-1.6
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$443.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$331.00 K
|
-$117.00 K
|
-$24.00 K
|
| Net Income |
-$190.89 M
|
-$257.59 M
|
-$327.27 M
|
-$340.41 M
|
-$182.05 M
|
-$250.22 M
|
-$184.59 M
|
-$211.51 M
|
-$2.00 K
|
| Net Income Ratio |
0
|
-11708.64
|
-3444.89
|
-2182.14
|
-1.6
|
0
|
0
|
0
|
0
|
| EPS |
-0.87 |
-1.32 |
-2.09 |
-2.38 |
-1.34 |
-2.08 |
-1.83 |
-2.36 |
-4.54429E-5 |
| EPS Diluted |
-0.87 |
-1.32 |
-2.09 |
-2.38 |
-1.34 |
-2.08 |
-1.83 |
-2.36 |
-4.54429E-5 |
| Weighted Average Shares Out |
$220.62 M
|
$194.81 M
|
$156.93 M
|
$143.15 M
|
$135.82 M
|
$120.37 M
|
$101.06 M
|
$89.69 M
|
$44.01 M
|
| Weighted Average Shares Out Diluted |
$220.62 M
|
$194.81 M
|
$156.93 M
|
$143.15 M
|
$135.82 M
|
$120.37 M
|
$101.06 M
|
$89.69 M
|
$44.01 M
|
| Link |
|
|
|
|
|
|
|
|
|
